NCT06779097Not yet recruitingPhase 4
A Prospective, Single-arm, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Vunakizumab in Adults With Moderate-to-severe Plaque Psoriasis Who Have Converted From Other Biologics
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1 site in 1 country1,564 target enrollmentStarted: February 2025Last updated:
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Enrollment
- 1,564
- Locations
- 1
- Primary Endpoint
- The proportion of subjects who achieved at least a 90% improvement from baseline in PASI scores by week 12 (PASI 90).
Study Overview
Brief Summary
This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque psoriasis who have converted from other biologics. To explore the efficacy of difficult-to-treat area, patient satisfaction and patient-reported outcomes (PRO).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥18 years old at the time of signing the informed consent, regardless of gender;
- •Diagnosed with moderate to severe plaque psoriasis;
- •The subject voluntarily signs informed consent before the start of any procedures related to the study, can communicate with the researcher smoothly, understands and is willing to strictly comply with the requirements of this clinical study protocol to complete the study;
- •Patients who have been treated with biologics for ≥12 weeks prior to screening and are in line with the biologics conversion recommendations of the Chinese Guidelines for the Treatment of Psoriasis Biologics and Small Molecule Drugs (2024 edition), and who have been screened and evaluated by researchers as eligible for biologics therapy.
Exclusion Criteria
- •Patients previously treated with IL-17A inhibitors (IL-17Ai) had primary failure;
- •Patients who had previously used IL-17A inhibitors (IL-17Ai) and experienced drug-related adverse events leading to drug withdrawal;
- •Patients with severe hypersensitivity to the active ingredient or any excipients of Vunakizumab;
- •Fertile women (defined as all women with physical conditions necessary for pregnancy) and men who are pregnant or unwilling or unable to use highly effective birth control during the study period and within 20 weeks after the last receipt of the study drug;
- •Patients with clinically important active diseases, such as active tuberculosis, active hepatitis, and active malignant tumors;
- •Any other circumstances that the investigator believes will prevent the subject from following and completing the study protocol.
Arms & Interventions
Vunakizumab (IL-17A inhibitor)
Experimental
Intervention: Vunakizumab (IL-17A inhibitor) (Drug)
Outcomes
Primary Outcomes
The proportion of subjects who achieved at least a 90% improvement from baseline in PASI scores by week 12 (PASI 90).
Time Frame: Three months
Proportion of subjects achieving sPGA 0/1 response at week 12.
Time Frame: Three months
Secondary Outcomes
- Proportion of subjects with PASI 75, PASI 90, PASI 100, sPGA 0/1, and sPGA 0 at week 4, 12, and 52.(One month， Three months，Twelve months)
- The time when subjects reached PASI 75 and PASI 90 within 12 weeks(Three months)
- The time when subjects reached PASI 75, PASI 90, PASI 100 within 52 weeks.(Twelve months)
- Changes in PASI scores relative to baseline at each visit during 52 weeks.(Twelve months)
- Response rates of ACR (American College of Rheumatology) 20, ACR50 and ACR70 at week 4, 12, 24 and 52.(One month， Three months， Six months，Twelve months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque PsoriasisModerate to Severe Plaque PsoriasisNCT06696417First Hospital of China Medical University1,516
Completed
Phase 4
A clinical study to assess the efficacy and safety of Glycopyrrolate, Formoterol Fumarate and Budesonide Inhalation in patients with Chronic Obstructive Pulmonary DiseaseCTRI/2023/03/050717Zydus Healthcare Limited200
Not yet recruiting
Phase 4
A prospective, single-arm, multi-center phase IV clinical research to evaluate the safety of Jinhua Qinggan Granules in the treatment of influenzaInfluenzaITMCTR2100005166Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University
Completed
Phase 4
Safety and Efficacy of Amantadine Tablets for the Treatment of Parkinsons Disease (A disorder of the central nervous system that affects movement, often including tremors) and Drug-induced Extrapyramidal Reactions (involuntary or uncontrollable movements, tremors, muscle contractions) in PatientsCTRI/2023/04/051973Sun Pharma Laboratories Limited (SPLL)163
Not yet recruiting
Phase 4
Safety and efficacy of Brinzolamide and Timolol eye drops to decrease intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension for whom single drug therapy provides insufficient for intraocular pressure reductioCTRI/2023/05/052720Sun Pharma Laboratories Limited (SPLL)